⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL7533244 | 0.97 | TDP1 (0.36) | — | |
| SCHEMBL7167424 | 0.76 | TDP1 (0.39) | — | |
| SCHEMBL7415432 | 0.75 | LMNA (0.36) | — | |
| SCHEMBL7713378 | 0.75 | — | — | |
| SCHEMBL27831096 | 0.74 | — | — | |
| SCHEMBL501173 | 0.73 | KDM4E (0.34) | — | |
| Creatine SCHEMBL30063981 | 0.72 | — | — | |
| SCHEMBL11531778 | 0.72 | TDP1 (0.36) | — | |
| Creatine SCHEMBL21567 | 0.72 | — | — | |
| Creatine SCHEMBL27979093 | 0.72 | NOS3 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1097580-C | Aminoguanidine carboxylates for the treatment of non-insulin dependent diabetes mellitus | BIOVITRUM AB (SE) | 2003-01-01 | — | — | CN | claimed |
| US-6166080-A | Aminoquanidine carboxylates for the treatment of obesity | PHARMACIA (US) | 2000-12-26 | — | — | US | claimed |
| CN-1164226-A | Aminoguanidine carboxylates for the treatment of non-insulin dependent diabetes mellitus | UPJOHN CO (US) | 1997-11-05 | — | — | CN | claimed |
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| WO-2023004308-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3137447-B1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX INC (US) | 2021-06-30 | — | — | EP | disclosed |
| EP-3137447-B1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX INC (US) | 2021-06-30 | — | — | EP | disclosed |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190315680-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20190315680-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2019-10-17 | — | — | US | disclosed |
| US-10308597-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10308597-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20170050924-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050924-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050924-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2017-02-23 | — | — | US | disclosed |
| CN-1377642-A | Use of compound for preparing medicine for curing and preventing non-insulin dependent diabetes or obesity | BIOVITRUM AB (SE) | 2002-11-06 | — | — | CN | disclosed |
| CN-1164226-A | Aminoguanidine carboxylates for the treatment of non-insulin dependent diabetes mellitus | UPJOHN CO (US) | 1997-11-05 | — | — | CN | disclosed |